Crescent Biopharma宣布，美国食品药品监督管理局（FDA）已对其在研药物Cr-002的临床试验申请（IND）亮起绿灯。这款药物是一种靶向PD-L1的拓扑异构酶抑制剂抗体偶联药物（ADC），拟用于实体瘤的治疗。
Crescent Biopharma宣布，美国食品药品监督管理局（FDA）已对其在研药物Cr-002的临床试验申请（IND）亮起绿灯。这款药物是一种靶向PD-L1的拓扑异构酶抑制剂抗体偶联药物（ADC），拟用于实体瘤的治疗。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.